NEW YORK (GenomeWeb News) – Investment firm Lazard Capital today initiated coverage of Sequenom’s stock with a “Buy” rating and a price target of $20.
Sequenom’s shares were trading up 3.2 percent at $7.79 in early Friday trading on the Nasdaq.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.